Opinion
- Author:
- Alan P. Lyss, MD
Publish date: September 16, 2019
Dr. Alan P. Lyss dissects the clinical significance of two recent studies that examine the long-term survival of patients with stage IV non–small c...
Opinion
- Author:
- Alan P. Lyss, MD
Publish date: August 30, 2019
Dr. Alan P. Lyss looks at the immune-related adverse events in patients on immune checkpoint inhibitors and the effect of delays in starting system...
Opinion
- Author:
- Alan P. Lyss, MD
Publish date: August 16, 2019
Dr. Alan P. Lyss explores the complexity of shared decision-making in cancer screening.
Opinion
- Author:
- Alan P. Lyss, MD
Publish date: August 2, 2019
Two trials raise important questions about the treatment of non-small cell lung cancer in the age of immuno-oncology, but the findings aren’t matur...
Opinion
- Author:
- Alan P. Lyss, MD
Publish date: July 19, 2019
Dr. Alan P. Lyss dissects the practice changing elements of the COLUMBA trial in multiple myeloma and the ASCEND trial in CLL.
Opinion
- Author:
- Alan P. Lyss, MD
Publish date: July 8, 2019
Dr. Alan Lyss examines the latest research on predicting VTE risk in patients with acute leukemia and new data on the impact of steroids in non–sma...
Article
- Author:
- Alan P. Lyss, MD
Publish date: June 21, 2019
Dr. Alan P. Lyss breaks down new data presented on immune checkpoint inhibitors in NSCLC and trastuzumab emtansine for HER2-positive breast cancer....
Opinion
- Author:
- Alan P. Lyss, MD
Publish date: June 8, 2019
Dr. Alan P. Lyss looks at two recent reports about treatment in non–small cell lung cancer.
Opinion
- Author:
- Alan P. Lyss, MD
Publish date: May 22, 2019
Dr. Lyss breaks down the results of the ARCHES trial and new data on ctDNA monitoring in early colorectal cancer.
Opinion
- Author:
- Alan P. Lyss, MD
Publish date: April 25, 2019
Dr. Alan P. Lyss breaks down the clinical relevance of two recent studies in advanced cervical cancer and diffuse large B-cell lymphoma.
Opinion
- Author:
- Alan P. Lyss, MD
Publish date: April 12, 2019
In “How I will treat my next patient,” Dr. Alan P. Lyss analyzes the latest literature and breaks down what it means for everyday practice.
